Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression

Murdamoothoo, D; Sun, Z; Yilmaz, A; Riegel, G; Abou-Faycal, C; Deligne, C; Velazquez-Quesada, I; Erne, W; Nascimento, M; Morgelin, M; Cremel, G; Paul, N; Carapito, R; Veber, R; Dumortier, H; Yuan, JP; Midwood, KS; Loustau, T; Orend, G

Orend, G (corresponding author), Hop Civil, Inst Hematol & Immunol, Tumor Microenvironm Lab, Fac Med,INSERM,UMR S 1109, Strasbourg, France.; Orend, G (corresponding author), INSERM, Fac Med, Microenvironm Niche Tumorigenesis & Targeted Ther, UMR S 1109, Hautepierre, France.; Orend, G (corresponding author), Univ Strasbourg, Strasbourg, France.; Orend, G (corresponding author), Federat Med Translat Strasbourg FMTS, Strasbourg, France.

EMBO MOLECULAR MEDICINE, 2021; 13 (6):

Abstract

Immune checkpoint therapy, where CD8 tumor infiltrating T lymphocytes (TIL) are reactivated, is a promising anti-cancer treatment approach, yet with l......

Full Text Link